A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT07547228 | Recruiting Phase 1 DMC

• 1 other identifier: 01/2024
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD). PRL3-zumab will be administered intravenously in 2-week interval for 3 doses. Normal saline (0.9% Sodium Chloride w/v) will be used in placebo treatment. The study will consist of 3 arms. Arm-1: PRL3-zumab 3mg/kg intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-2: PRL3-zumab 6mg/kg intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-3: Placebo (normal saline 0.9% sodium chloride w/v) intravenously will be administered in 2 week interval followed by 20 weeks of monitoring (n=3) Initial 3 arms will be conducted on patients who failed Standard-of-Care (SOC) therapy. Response assessment will be done at every 4 weeks from last dose of treatment till 24-week. Randomization: Randomization will be done in 2:2:1 manner on PRL3-zumab (Arm 1), 3mg/kg (n=6); PRL3-zumab (Arm 2), 6mg/kg (n=6); and placebo group (Arm 3) (n=3). Randomization can be achieved using random number table which will be prepared before the commencement of clinical trial. The allocation of participants will be done by Investigator and will be concealed from the participants. Blinding: Single blinding will be done for this trial in which all participants are unaware of their treatment assignment. No blinding will be done on Investigator. Primary Endpoints:

• Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score. Change in BCVA letter gain of 0-4 will be considered as primary end point.
• Change From Baseline in Central Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT). \[Assessment Time Frame: 4 weekly through 24 weeks\] Secondary endpoints:
• Change in visual Acuity (Best Corrected Visual Acuity) of 5 or more letters.
• Proportion of patients gaining ≥15, ≥10, ≥5, or ≥0 ETDRS letters in BCVA from baseline over time
• Proportion of patients avoiding a loss of ≥15, ≥10, or ≥5 ETDRS letters in BCVA from baseline over time
• Proportion of patients with absence of intraretinal fluid measured by OCT
• Proportion of patients with absence of subretinal fluid measured by OCT \[Assessment Time Frame: 4 weekly through 24 weeks\] Criteria for additional Therapy: Once the treatment is stopped after the third dose, patients from all groups are eligible for additional therapy as open-label treatment if there is recurrence of disease activity, as defined by presence of any of the following criteria:
• Decrease of ≥5 letters in BCVA compared with average BCVA value over the previous two scheduled visits, owing to nAMD disease activity (as determined by the investigator).
• Increase of \>50 µm in OCT-measured CST compared with the average CST value over the previous two scheduled visits.
• Recurrence of intra-retinal or sub-retinal fluid (if resolved previously)
• New macular hemorrhage
• BCVA decreases by 15 letters or more from best recorded BCVA because of nAMD disease activity.
• an increase in OCT central retinal thickness 150 µm or more from lowest recorded measurement after 2 consecutive additional therapy occurring 1 month apart.

Conditions

Neovascular Age Related Macular Degeneration

Keywords

PRL3; PRL3-zumab; nAMD; Neovasclar Age Related Macular Degeneration; Wet AMD

Outcome Measures

Primary Outcomes (4)

• Safety: Adverse Events according to CTCAE

  Frequency and severity of adverse events throughout the primary outcome assessment period will be assessed by the Investigator for severity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 or later.

  24 weeks

• Recommended Phase 2 Dose (PR2D)

  This study will confirm RP2D established from Phase I Clinical Trial conducted in National University Hospital (NUH) Singapore in Cancer patients (MC/03/0616).

  24 weeks

• Efficacy: Best Corrected Visual Acuity (BCVA) measured by ETDRS letter score

  Change From Baseline in Best Corrected Visual Acuity (BCVA) measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score will be monitored. Change in BCVA letter gains of 0-4 will be considered as primary outcome measure.

  24 weeks

• Efficacy: Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT)

  Change from Baseline in Central Subfield Retinal Thickness (CST) measured by Optical Coherence Tomography (OCT) will be monitored

  24 weeks

Secondary Outcomes (3)

• Best Corrected Visual Acuity (BCVA) measured by ETDRS letter score

  24 weeks

• Intraretinal fluid measured by Optical Coherence Tomography (OCT)

  24 weeks

• Subretinal fluid measured by Optical Coherence Tomography (OCT)

  24 weeks

Study Arms (3)

Group 1: PRL3-zumab 3mg/kg

EXPERIMENTAL

Biological: PRL3-ZUMAB

Group 2: PRL3-zumab 6mg/kg

EXPERIMENTAL

Biological: PRL3-ZUMAB

Group 3: Placebo

PLACEBO COMPARATOR

Other: Normal Saline (0.9% Sodium Chloride)

Interventions

PRL3-ZUMAB BIOLOGICAL

The study will consist of 3 arms, PRL3-zumab 3mg/kg, 6mg/kg and placebo. PRL3-zumab will be administered intravenously in 2-week interval for 3 doses.

Group 1: PRL3-zumab 3mg/kg; Group 2: PRL3-zumab 6mg/kg

Normal Saline (0.9% Sodium Chloride) OTHER

Placebo group will be administered with normal saline, administered intravenously in 2-week interval for 3 doses.

Group 3: Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with Neovascular Age-related Macular Degeneration (nAMD).
• Willing to provide written informed consent for the study.
• Patients undergoing intravitreal treatment having failed at least two Standard-of care treatments and be receiving ongoing intravitreal treatment at intervals of ≤ 8 weeks including Ranibizumab, Aflibercept, or Faricimab.
• Participants receiving intravitreal treatment at screening must complete a wash-out period before enrolment. This wash-out period should be calculated based on five half-lives of the specific intravitreal treatment the participant is receiving.
• Below is the washing out period for some standard of care treatments.
• Ranibizumab (half-life: 9 days) requires a wash-out period of 45 days (7 weeks)
• Aflibercept (half-life: 11 days) requires a wash-out period of 55 days (8 weeks)
• Faricimab (half-life: 7.5 days) requires a wash-out period of 37.5 days (5 weeks)
• Bevacizumab (half-life: 6 days) requires a wash-out period of 30 days (4weeks)
• Subfoveal CNV or juxtafoveal/extrafoveal CNV with a subfoveal component related to the CNV activity identified by FFA or OCT (where CNV activity is defined as showing evidence of subretinal fluid, subretinal hyperreflective material, or leakage).
• BCVA ETDRS letter score of 78 to 24 (corresponding to a Snellen equivalent of approximately 20/32 to 20/320) in the study eye.
• Decrease in BCVA determined to be primarily the result of nAMD or DR/DME in the study eye.
• Presence of pigment epithelium detachment (PED), intraretinal fluid (IRF) and/or subretinal fluid (SRF) affecting the central subfield of the study eye on OCT.
• Adequate organ (liver and renal) and hematological functions as evidenced by the laboratory results obtained within 7 days of treatment which are within the normal range for the study population, or with abnormalities deemed not clinically significant by the investigators.

You may not qualify if:

• Scar, fibrosis, atrophy, or retinal pigment epithelial tears involving the central fovea in the study eye.
• Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with antiglaucoma medication) in the study eye.
• History of idiopathic or autoimmune uveitis in the study eye.
• Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.
• Evidence of extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening/randomization.
• Uncontrolled blood pressure (defined as systolic \>160 mmHg or diastolic \>95 mmHg).
• Patient is receiving systemic glucocorticoids (only if higher than 10mg or equivalent of prednisolone daily) or other immunosuppressive treatment for autoimmune disease or any other medical condition.

Sponsors & Collaborators

• Intra-IMMUSG Pte Ltd: lead
• National University Hospital, Singapore: collaborator

Study Sites (1)

NUHS Department of Ophthalmology

Singapore, Singapore

RECRUITING

Related Links

• PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases
• A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies

MeSH Terms

Interventions

Saline Solution; Sodium Chloride

Intervention Hierarchy (Ancestors)

Crystalloid Solutions; Isotonic Solutions; Solutions; Pharmaceutical Preparations; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Officials

• Prof Qi Zeng

  Intra-IMMUSG Pte Ltd

  STUDY DIRECTOR

Central Study Contacts

Dr Koon Hwee Ang (David)

CONTACT

+65 65869661; ang.koonhwee@intra-immusg.com

Dr Min Thura

CONTACT

min.thura@intra-immusg.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The study consists of 3 arms (1) PRL3-zumab 3mg/kg (2) PRL3-zumab 6mg/kg and (3) Placebo

Study Record Dates

• First Submitted: April 17, 2026
• First Posted: April 23, 2026
• Study Start: October 11, 2025
• Primary Completion (Estimated): February 7, 2027
• Study Completion (Estimated): July 7, 2027
• Last Updated: April 29, 2026

Record last verified: 2026-04

Locations

SG (1)